Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 18042149)

1.

The genome and epigenome of malignant melanoma.

Dahl C, Guldberg P.

APMIS. 2007 Oct;115(10):1161-76. Review.

PMID:
18042149
2.

KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK.

Clin Cancer Res. 2011 Jun 15;17(12):3933-42. doi: 10.1158/1078-0432.CCR-10-2917.

3.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
4.

High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma.

Jonsson A, Tuominen R, Grafström E, Hansson J, Egyhazi S.

J Invest Dermatol. 2010 Dec;130(12):2809-17. doi: 10.1038/jid.2010.216. Epub 2010 Aug 12.

5.

Distinct sets of genetic alterations in melanoma.

Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC.

N Engl J Med. 2005 Nov 17;353(20):2135-47.

6.

BRAF alterations are associated with complex mutational profiles in malignant melanoma.

Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M.

Oncogene. 2004 Aug 5;23(35):5968-77.

PMID:
15195137
7.

BRAF somatic mutations in malignant melanoma and melanocytic naevi.

Thomas NE.

Melanoma Res. 2006 Apr;16(2):97-103. Review.

PMID:
16567964
9.

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.

Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA.

Nat Genet. 2005 Jul;37(7):745-9. Epub 2005 Jun 12.

10.

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.

Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL.

Cancer Res. 2004 Aug 15;64(16):5556-9.

11.

Detection of BRAF gene mutation in primary choroidal melanoma tissue.

Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F, Mazzarino MC, Stivala F, McCubrey JA, Travali S.

Cancer Biol Ther. 2006 Feb;5(2):225-7. Epub 2006 Feb 20.

PMID:
16410717
12.

Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.

Indsto JO, Kumar S, Wang L, Crotty KA, Arbuckle SM, Mann GJ.

J Cutan Pathol. 2007 Jun;34(6):448-55.

PMID:
17518771
13.

Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.

Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC.

J Invest Dermatol. 2008 Aug;128(8):2003-12. doi: 10.1038/jid.2008.30. Epub 2008 Mar 6.

14.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

15.

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.

Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, Brinckerhoff CE.

J Biol Chem. 2004 Aug 6;279(32):33168-76. Epub 2004 Jun 7.

16.

MicroRNAs in the pathogenesis of malignant melanoma.

Glud M, Gniadecki R.

J Eur Acad Dermatol Venereol. 2013 Feb;27(2):142-50. doi: 10.1111/j.1468-3083.2012.04579.x. Epub 2012 May 23. Review.

PMID:
22621697
17.

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM.

J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. Review.

PMID:
21302297
18.

Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.

Edmunds SC, Kelsell DP, Hungerford JL, Cree IA.

Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2845-51.

PMID:
12202501
19.

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman LS, Belvin M.

Cancer Res. 2009 Apr 1;69(7):3042-51. doi: 10.1158/0008-5472.CAN-08-3563. Epub 2009 Mar 10.

20.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk